Last updated: October 17, 2026
Opdivo, Bristol Myers Squibb’s nivolumab, generated approximately $9.0 billion in global revenue in 2023, making it one of the company’s largest products. Revenue growth has continued as BMS expands use in earlier-stage cancers and combination regimens, but Keytruda’s stronger market position limits share gains. The main medium-term risks are the maturation of the PD-1 market, future biosimilar competition, royalty obligations to Merck, and patent expiry beginning with core composition-of-matter protection in the United States in 2028.
How much revenue does Opdivo generate?
Opdivo revenue has increased substantially since its 2014 launch, supported by more than a dozen approved indications across solid tumors and hematologic cancers.
| Fiscal year |
Opdivo revenue |
Year-over-year change |
Commercial position |
| 2020 |
Approximately $6.99 billion |
Approximately 7% |
Established global oncology franchise |
| 2021 |
Approximately $7.52 billion |
Approximately 8% |
Growth from lung, renal, esophageal, and other cancers |
| 2022 |
Approximately $8.21 billion |
Approximately 9% |
Continued indication expansion |
| 2023 |
Approximately $9.01 billion |
Approximately 10% |
Record sales and broader perioperative use |
| 2024 onward |
Not included in the table |
— |
Dependent on new indications, combination penetration, and competitive durability |
Sources: Bristol Myers Squibb annual reports and company earnings disclosures.[1][2][3]
Opdivo represented roughly 30% of Bristol Myers Squibb’s 2023 total revenue and approximately 46% of the company’s Innovative Medicines revenue. The product is strategically important because it is a high-margin biologic with a broad label and a large installed base of oncology prescribers.
The financial profile is more resilient than that of a single-indication oncology product because revenue is distributed across multiple tumor types. That diversification reduces the impact of generic entry into any one chemotherapy combination, but it does not eliminate exposure to PD-1 class competition.
What is driving Opdivo’s market growth?
Opdivo growth is driven by earlier treatment settings, combination therapy, and expansion into cancers where immune checkpoint inhibition has a favorable clinical profile.
Earlier-stage and perioperative treatment
The most important growth opportunity is movement from advanced disease into adjuvant and neoadjuvant treatment. Earlier-stage use increases the treated patient population and extends duration of therapy in selected settings.
Major growth areas include:
- Non-small cell lung cancer, including neoadjuvant and adjuvant use.
- Bladder and urothelial cancer.
- Esophageal and gastroesophageal junction cancer.
- Renal cell carcinoma.
- Melanoma.
- Head and neck cancer.
- Gastric and colorectal cancers in biomarker-defined populations.
- Resectable esophageal and gastroesophageal cancers.
FDA approvals have increasingly involved combination regimens, including Opdivo with ipilimumab, chemotherapy, cabozantinib, or other agents depending on the indication.[4]
Combination therapy
Combination therapy increases clinical utility but can complicate pricing and revenue attribution. Opdivo is marketed with:
- Yervoy, or ipilimumab.
- Chemotherapy.
- Cabometyx, or cabozantinib, in renal cell carcinoma.
- Relatlimab through the Opdualag fixed-dose combination.
Opdualag is commercially important because it extends the nivolumab franchise into a differentiated LAG-3/PD-1 combination. It can also shift some patients from standalone Opdivo to a newer combination product, creating potential franchise cannibalization while preserving BMS revenue.
International expansion
Opdivo has broad regulatory coverage in the United States, Europe, Japan, China, and other major oncology markets. International sales support growth, but pricing and reimbursement are more constrained outside the United States. Market access decisions often depend on biomarker testing, line of therapy, and health-economic evidence.
How does Opdivo compare with Keytruda?
Keytruda is the dominant PD-1 product and has a materially larger commercial base. Opdivo remains a major competitor because of its broad label, strong efficacy data in several cancers, and extensive combination program.
| Factor |
Opdivo |
Keytruda |
| Active ingredient |
Nivolumab |
Pembrolizumab |
| Manufacturer |
Bristol Myers Squibb and Ono Pharmaceutical |
Merck |
| First U.S. approval |
2014 |
2014 |
| Core mechanism |
PD-1 inhibition |
PD-1 inhibition |
| 2023 global revenue |
Approximately $9.0 billion |
Approximately $25.0 billion |
| Main commercial strength |
Broad combination and perioperative oncology portfolio |
Larger first-line market share and wider label |
| Key competitive advantage |
Strong combination data and established use in multiple tumor types |
Earlier approval, larger commercial footprint, extensive monotherapy use |
| Biosimilar exposure |
Expected after biologic exclusivity and patent expiry |
Expected after biologic exclusivity and patent expiry |
| Royalty burden |
Royalties owed under PD-1 settlement arrangements |
Also subject to PD-1 patent settlement economics |
Keytruda’s advantage is strongest in first-line metastatic disease, where Merck has built substantial prescribing momentum. Opdivo is more competitive in selected combination regimens and disease settings where trial results, dosing preferences, or local treatment guidelines favor nivolumab.
The financial gap between the products reflects commercial execution, label breadth, clinical trial sequencing, and physician adoption. Opdivo does not need to displace Keytruda across the entire PD-1 market to remain valuable, but it must defend its existing indications while growing earlier-line use.
What patents protect Opdivo?
Opdivo is protected by a portfolio of biologic, formulation, manufacturing, and method-of-use rights. The principal U.S. composition-of-matter patent commonly associated with nivolumab is U.S. Patent No. 8,008,449, which has an expiration date in September 2028 before any applicable patent-term adjustment or pediatric extension.[5]
| Protection category |
Opdivo relevance |
Commercial effect |
| Antibody composition |
Covers nivolumab or related anti-PD-1 antibodies |
Primary barrier to biosimilar competition |
| Formulation |
Covers stable liquid or concentrated antibody formulations |
Can extend protection for particular presentations |
| Manufacturing process |
Covers cell culture, purification, or production methods |
Raises development and technical barriers |
| Method of treatment |
Covers use in specific cancers or combination regimens |
Supports indication-specific enforcement |
| Combination therapy |
Covers nivolumab with ipilimumab, chemotherapy, or other agents |
Protects selected treatment protocols |
| Regulatory exclusivity |
FDA biologic reference-product exclusivity |
Delays biosimilar approval independent of patent validity |
The practical protection period is longer than the earliest patent date because patents covering formulations, dosing regimens, manufacturing, or specific indications may expire later. Those secondary patents do not necessarily prevent all biosimilar entry if a competitor can design around them.
When does Opdivo lose exclusivity?
Opdivo’s FDA reference-product biologic exclusivity began with its first U.S. approval on December 22, 2014. Under the Biologics Price Competition and Innovation Act, the 12-year reference-product exclusivity period generally extends to December 2026.[6]
The key U.S. dates are:
| Event |
Date or period |
| FDA approval of Opdivo |
December 22, 2014 |
| Earliest potential biosimilar approval based on 12-year exclusivity |
December 2026 |
| Core U.S. patent expiration commonly cited for nivolumab |
September 2028 |
| Likely first practical U.S. biosimilar launch window |
2028 onward, subject to litigation and patent strategy |
| Full erosion risk |
More likely in the early 2030s than immediately after 2026 |
The 2026 biologic exclusivity date does not guarantee biosimilar market entry. A biosimilar sponsor may file under the BPCIA after the statutory filing window, but patent litigation, settlement terms, manufacturing readiness, and FDA review timing determine the launch date.
What is the FDA and Orange Book status of Opdivo?
Opdivo is approved under a biologics license application, BLA 125554. It is not an ordinary small-molecule drug listed in the Orange Book.
The applicable FDA reference for biologics is the Purple Book, which identifies licensed biological products and biosimilar or interchangeable products. An abbreviated new drug application and Paragraph IV certification are not the standard pathway for a nivolumab biosimilar.
How do Paragraph IV challenges apply?
Paragraph IV litigation is associated with Hatch-Waxman ANDA filings for small-molecule drugs. A biosimilar sponsor challenging Opdivo would proceed under the BPCIA framework rather than submitting a conventional Paragraph IV certification.
Potential BPCIA disputes could involve:
- Whether the biosimilar infringes core antibody patents.
- Whether formulation and manufacturing patents are valid.
- Whether method-of-use patents are relevant to the proposed label.
- Whether the biosimilar sponsor follows the statutory patent-exchange process.
- Whether the parties negotiate an agreed launch date.
As of mid-2024, no U.S. Opdivo biosimilar had been approved by FDA, and no biosimilar had established a commercial launch position comparable to the emerging biosimilar programs for older anti-TNF or oncology biologics.
What patent litigation affects Opdivo?
The most important patent dispute affecting the nivolumab franchise is the historical PD-1 litigation between Bristol Myers Squibb, Ono Pharmaceutical, and Merck.
The parties resolved U.S. and international disputes through settlement arrangements under which Merck paid an upfront amount and agreed to royalty obligations tied to Keytruda sales. The settlement reduced immediate litigation risk but created a continuing economic transfer between competing PD-1 franchises.[7]
For Opdivo, the settlement has two effects:
- It removed the risk of a disruptive injunction or invalidity outcome against the broader PD-1 business.
- It reduced net economics through royalty payments associated with Merck’s competing product.
Future litigation is more likely to involve biosimilar applicants and secondary patents than a direct challenge to the basic commercial concept of PD-1 inhibition.
How strong is the Opdivo patent estate?
Opdivo has a strong commercial patent estate through the late 2020s, but the estate becomes more vulnerable after core composition protection expires.
Strengths
- Broad biologic reference-product exclusivity through 2026.
- Core U.S. antibody patent protection extending into 2028.
- Large global portfolio covering treatment methods and formulations.
- Manufacturing complexity associated with monoclonal antibodies.
- Multiple approved indications that may be protected by separate method-of-use claims.
- High clinical and regulatory barriers for biosimilar development.
Weaknesses
- Biosimilar sponsors can potentially avoid some method-of-use patents through label carving.
- Secondary patents may be vulnerable to validity challenges.
- The product has a large commercial target, making it attractive to biosimilar developers.
- PD-1 antibodies are clinically established, reducing regulatory and physician-adoption risk for future biosimilars.
- Competition from Keytruda and other checkpoint inhibitors limits pricing power before biosimilar entry.
The strongest barrier is the combination of regulatory complexity, antibody manufacturing, and core patent protection. The weakest protection category is often indication-specific method-of-use coverage when a biosimilar can omit patented uses from its label.
What biosimilar risk exists for Opdivo?
Opdivo faces low near-term biosimilar risk and increasing medium-term risk.
Near-term risk: 2024-2026
The principal risks are competitive rather than biosimilar-related. Keytruda, Tecentriq, Imfinzi, Libtayo, and emerging immuno-oncology combinations compete for the same patients. Pricing pressure may develop through payer contracting and hospital procurement even without biosimilar entry.
Medium-term risk: 2027-2030
Biosimilar developers are likely to evaluate nivolumab because:
- The market is large.
- The product has broad use across multiple tumor types.
- The molecule is commercially validated.
- Reference-product exclusivity approaches expiration.
- Biosimilar developers have accumulated experience with complex oncology antibodies.
Potential entrants could include large multinational biosimilar companies and oncology-focused manufacturers. No specific company had an FDA-approved nivolumab biosimilar as of mid-2024.
Long-term risk: after 2030
The market could experience several competing nivolumab biosimilars, contracting pressure, hospital formulary substitution, and accelerated use of lower-cost versions in indications with limited differentiation. The erosion curve is likely to be slower than for many small-molecule drugs because oncology treatment decisions are indication-specific and physicians may prefer established suppliers.
What manufacturing and intellectual-property barriers protect Opdivo?
Nivolumab is a recombinant monoclonal antibody manufactured through mammalian cell culture, purification, viral clearance, formulation, sterile filling, and cold-chain distribution. Biosimilar developers must demonstrate high similarity through analytical, functional, pharmacokinetic, immunogenicity, and clinical evidence appropriate to FDA requirements.
Manufacturing barriers include:
- Cell-line development and process control.
- Glycosylation and product-quality consistency.
- Aggregation and stability control.
- Scale-up and sterile manufacturing capacity.
- Analytical comparability.
- Supply reliability for global oncology demand.
These barriers do not prevent biosimilar competition, but they increase development cost and reduce the number of credible entrants. A successful biosimilar may also need to demonstrate supply reliability across multiple tumor indications and reimbursement systems.
Which companies challenge Opdivo commercially?
The competitive landscape includes direct PD-1 or PD-L1 products and combination therapies.
| Competitor |
Company |
Main competitive position |
| Keytruda |
Merck |
Leading PD-1 product with broad first-line use |
| Tecentriq |
Roche |
PD-L1 inhibitor with lung, urothelial, and other indications |
| Imfinzi |
AstraZeneca |
Strong lung cancer and biliary tract position |
| Libtayo |
Regeneron and Sanofi |
PD-1 use in selected skin and lung cancers |
| Bavencio |
Pfizer and Merck KGaA |
Urothelial and other selected indications |
| Emerging combinations |
Multiple companies |
Compete through dual immunotherapy, antibody-drug conjugates, and targeted combinations |
The most serious commercial threat remains Keytruda. Other checkpoint inhibitors matter more in specific tumor types than across the entire franchise.
What are the likely generic and biosimilar launch scenarios?
A conventional generic launch is not available for Opdivo because it is a biologic. The relevant scenarios are:
Scenario 1: Delayed biosimilar entry
Biosimilar launch occurs after core patent expiry and negotiated litigation settlements. Opdivo revenue continues growing through the late 2020s before declining gradually.
Scenario 2: Early settlement-based entry
One or more biosimilar sponsors reach settlements allowing entry near or shortly after the 2028 patent date. Revenue erosion begins earlier but remains moderated by clinical complexity and indication-specific adoption.
Scenario 3: Multiple-biosimilar entry
Several products enter after 2028, producing greater price compression and hospital-level substitution. This would create the highest revenue risk, particularly in mature indications.
Scenario 4: Franchise migration
BMS shifts part of the nivolumab franchise into Opdualag, new fixed-dose combinations, or protected formulations. This can preserve some revenue but may not fully offset erosion of standalone Opdivo.
What is the financial outlook for Opdivo?
Opdivo’s financial trajectory is likely to have three phases:
- Continued growth through indication expansion and earlier-stage treatment.
- Slower growth as Keytruda retains market leadership and the PD-1 class matures.
- Gradual erosion after core patent expiry and eventual biosimilar entry.
The product’s revenue base has enough diversification to support substantial sales through the late 2020s. Its largest financial risks are not immediate loss of exclusivity but declining incremental benefit from new indications, competitive pressure in first-line disease, and the need to share economics with combination partners and royalty recipients.
BMS also faces the broader issue of portfolio concentration. Opdivo is a major revenue contributor, while other products such as Eliquis face their own lifecycle and patent pressures. The company therefore has an incentive to protect the broader immuno-oncology franchise through combination products, perioperative indications, and next-generation assets.
Key Takeaways
- Opdivo generated approximately $9.0 billion in global revenue in 2023.
- Keytruda is the primary commercial competitor and has a substantially larger revenue base.
- FDA reference-product biologic exclusivity generally runs through December 2026.
- Core U.S. nivolumab patent protection is commonly cited as extending to September 2028.
- Paragraph IV challenges do not apply directly because Opdivo is a biologic; biosimilar disputes proceed under the BPCIA.
- No FDA-approved nivolumab biosimilar existed as of mid-2024.
- The strongest growth drivers are perioperative treatment, earlier-stage disease, and combination regimens.
- The principal long-term risk is biosimilar erosion after 2028, with commercial pressure likely to build through the early 2030s.
- Opdualag and other protected combinations can preserve part of the nivolumab franchise but may also cannibalize standalone Opdivo sales.
- Historical PD-1 litigation was resolved through settlement, reducing injunction risk but creating royalty obligations.
FAQs
Does Opdivo have a generic version?
No. Opdivo is a monoclonal antibody biologic, so any follow-on product would be a biosimilar rather than a conventional generic.
Is Opdivo listed in the FDA Orange Book?
No. Opdivo is regulated under a BLA and is referenced through the FDA Purple Book rather than the Orange Book.
When can a biosimilar manufacturer launch a nivolumab product?
The earliest practical launch window is generally expected after core patent protection expires, with 2028 or later being the key period for U.S. commercial entry.
What drug has the largest competitive impact on Opdivo sales?
Keytruda, Merck’s pembrolizumab, has the largest competitive impact because it has a broader commercial position and materially higher global revenue.
Can BMS extend Opdivo protection beyond 2028?
BMS may rely on later-expiring formulation, manufacturing, combination, and method-of-use patents. Those patents can delay or narrow biosimilar entry but may not prevent competition across all nivolumab indications.
References
- Bristol Myers Squibb. (2021). 2020 annual report.
- Bristol Myers Squibb. (2022). 2021 annual report.
- Bristol Myers Squibb. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2024). Opdivo prescribing information.
- U.S. Patent and Trademark Office. (2009). U.S. Patent No. 8,008,449: Human monoclonal antibodies to programmed death-1.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- Merck & Co., Inc. (2017). Merck announces resolution of patent litigation with Bristol-Myers Squibb and Ono Pharmaceutical.
